Central European Journal of Medicine

, Volume 8, Issue 3, pp 287–296 | Cite as

Predictors of diabetic nephropathy

  • Mahmoud R. Gaballa
  • Youssef M. K. Farag
Review Article


Diabetic nephropathy (DN) is a leading cause of morbidity and mortality in diabetic patients representing a huge health and economic burden. Alarming recent data described diabetes as an unprecedented worldwide epidemic, with a prevalence of ∼6.4% of the world population in 2010, while the prevalence of CKD among diabetics was approximately 40%. With a clinical field hungry for novel markers predicting DN, several clinical and laboratory markers were identified lately with the promise of reliable DN prediction. Among those are age, gender, hypertension, smoking, sex hormones and anemia. In addition, eccentric left ventricular geometric patterns, detected by echocardiography, and renal hypertrophy, revealed by ultrasonography, are promising new markers predicting DN development. Serum and urinary markers are still invaluable elements, including serum uric acid, microalbuminuria, macroalbuminuria, urinary liver-type fatty acid-binding protein (u-LFABP), and urinary nephrin. Moreover, studies have illustrated a tight relationship between obstructive sleep apnea and the development of DN. The purpose of this review is to present the latest advances in identifying promising predictors to DN, which will help guide the future research questions in this field. Aiming at limiting this paramount threat, further efforts are necessary to identify and control independent modifiable risk factors, while developing an integrative algorithm for utilization in DN future screening programs.


Diabetes Chronic kidney disease Diabetic nephropathy Risk factors Predictors Markers Microalbuminuria 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Foley, R.N. and A.J. Collins, The growing economic burden of diabetic kidney disease. Curr Diab Rep, 2009. 9(6): p. 460–465PubMedCrossRefGoogle Scholar
  2. [2]
    Farag, Y.M. and M.R. Gaballa, Diabesity: an overview of a rising epidemic. Nephrol Dial Transplant, 2011. 26(1): p. 28–35PubMedCrossRefGoogle Scholar
  3. [3]
    Shaw, J.E., R.A. Sicree, and P.Z. Zimmet, Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract, 2010. 87(1): p. 4–14PubMedCrossRefGoogle Scholar
  4. [4]
    Plantinga, L.C., et al., Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol, 2010. 5(4): p. 673–682PubMedCrossRefGoogle Scholar
  5. [5]
    Abougalambou, S.S.I., et al., Prevalence of Vascular Complications among Type 2 Diabetes Mellitus Outpatients at Teaching Hospital in Malaysia. J Diabet Metabol, 2011. 2:115CrossRefGoogle Scholar
  6. [6]
    Singh, D.K., P. Winocour, and K. Farrington, Oxidative stress in early diabetic nephropathy: fueling the fire. Nat Rev Endocrinol, 2010Google Scholar
  7. [7]
    Fioretto, P., et al., An overview of renal pathology in insulin-dependent diabetes mellitus in relationship to altered glomerular hemodynamics. Am J Kidney Dis, 1992. 20(6): p. 549–558Google Scholar
  8. [8]
    Adler, S., Diabetic nephropathy: Linking histology, cell biology, and genetics. Kidney Int, 2004. 66(5): p. 2095–2106PubMedCrossRefGoogle Scholar
  9. [9]
    Alexander, M.P., et al., Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis, 2009. 53(5): p. 751–759.CrossRefGoogle Scholar
  10. [10]
    Farag, Y.M., Metabolic syndrome and the nonneoplastic kidney. Adv Anat Pathol, 2011. 18(2): p. 173; author reply 174PubMedCrossRefGoogle Scholar
  11. [11]
    Nosadini, R., et al., Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes, 2000. 49(3): p. 476–484PubMedCrossRefGoogle Scholar
  12. [12]
    Keck, M., et al., Hormonal status affects the progression of STZ-induced diabetes and diabetic renal damage in the VCD mouse model of menopause. Am J Physiol Renal Physiol, 2007. 293(1): p. F193–199PubMedCrossRefGoogle Scholar
  13. [13]
    Mankhey, R.W., F. Bhatti, and C. Maric, 17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am J Physiol Renal Physiol, 2005. 288(2): p. F399–405PubMedCrossRefGoogle Scholar
  14. [14]
    Reckelhoff, J.F., et al., Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease. Am J Physiol Renal Physiol, 2005. 289(5): p. F941–948PubMedCrossRefGoogle Scholar
  15. [15]
    Mollsten, A., et al., Cumulative risk, age at onset, and sex-specific differences for developing endstage renal disease in young patients with type 1 diabetes: a nationwide population-based cohort study. Diabetes, 2010. 59(7): p. 1803–1808PubMedCrossRefGoogle Scholar
  16. [16]
    Morimoto, A., et al., Is pubertal onset a risk factor for blindness and renal replacement therapy in childhood-onset type 1 diabetes in Japan? Diabetes Care, 2007. 30(9): p. 2338–2340PubMedCrossRefGoogle Scholar
  17. [17]
    Harvey, J.N., The influence of sex and puberty on the progression of diabetic nephropathy and retinopathy. Diabetologia, 2011. 54(8): p. 1943–1945PubMedCrossRefGoogle Scholar
  18. [18]
    Finne, P., et al., Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA, 2005. 294(14): p. 1782–1787PubMedCrossRefGoogle Scholar
  19. [19]
    Raile, K., et al., Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care, 2007. 30(10): p. 2523–2528PubMedCrossRefGoogle Scholar
  20. [20]
    Svensson, M., et al., Age at onset of childhoodonset type 1 diabetes and the development of end-stage renal disease: a nationwide population-based study. Diabetes Care, 2006. 29(3): p. 538–542PubMedCrossRefGoogle Scholar
  21. [21]
    Dahlquist, G. and S. Rudberg, The prevalence of microalbuminuria in diabetic children and adolescents and its relation to puberty. Acta Paediatr Scand, 1987. 76(5): p. 795–800PubMedCrossRefGoogle Scholar
  22. [22]
    Olsen, B.S., et al., The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. J Diabetes Complications, 2004. 18(3): p. 160–164PubMedCrossRefGoogle Scholar
  23. [23]
    Yacoub, R., et al., Association between smoking and chronic kidney disease: a case control study. BMC Public Health, 2010. 10: p. 731.PubMedCrossRefGoogle Scholar
  24. [24]
    Sawicki, P.T., et al., Smoking is associated with progression of diabetic nephropathy. Diabetes Care, 1994. 17(2): p. 126–131PubMedCrossRefGoogle Scholar
  25. [25]
    Rossing, P., P. Hougaard, and H.H. Parving, Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care, 2002. 25(5): p. 859–864PubMedCrossRefGoogle Scholar
  26. [26]
    Stegmayr, B.G., A study of patients with diabetes mellitus (type 1) and end-stage renal failure: tobacco usage may increase risk of nephropathy and death. J Intern Med, 1990. 228(2): p. 121–124PubMedCrossRefGoogle Scholar
  27. [27]
    Chuahirun, T. and D.E. Wesson, Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite ACE inhibition. Am J Kidney Dis, 2002. 39(2): p. 376–382PubMedCrossRefGoogle Scholar
  28. [28]
    Orth, S.R., Smoking—a renal risk factor. Nephron, 2000. 86(1): p. 12–26PubMedCrossRefGoogle Scholar
  29. [29]
    Jaimes, E.A., R.X. Tian, and L. Raij, Nicotine: the link between cigarette smoking and the progression of renal injury? Am J Physiol Heart Circ Physiol, 2007. 292(1): p. H76–82PubMedCrossRefGoogle Scholar
  30. [30]
    Marangon, K., et al., Diet, antioxidant status, and smoking habits in French men. Am J Clin Nutr, 1998. 67(2): p. 231–239PubMedGoogle Scholar
  31. [31]
    Cross, C.E., A. van der Vliet, and J.P. Eiserich, Cigarette smokers and oxidant stress: a continuing mystery. Am J Clin Nutr, 1998. 67(2): p. 184–185PubMedGoogle Scholar
  32. [32]
    Hu, Y., et al., Relations of glycemic index and glycemic load with plasma oxidative stress markers. Am J Clin Nutr, 2006. 84(1): p. 70–76; quiz 266–267PubMedGoogle Scholar
  33. [33]
    Chabrashvili, T., et al., Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension, 2002. 39(2): p. 269–274PubMedCrossRefGoogle Scholar
  34. [34]
    Gorin, Y., et al., Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem, 2005. 280(47): p. 39616–39626PubMedCrossRefGoogle Scholar
  35. [35]
    Hua, P., et al., Nicotine worsens the severity of nephropathy in diabetic mice: implications for the progression of kidney disease in smokers. Am J Physiol Renal Physiol, 2010. 299(4): p. F732–739PubMedCrossRefGoogle Scholar
  36. [36]
    Sharma, K., P. McCue, and S.R. Dunn, Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol, 2003. 284(6): p. F1138–1144PubMedGoogle Scholar
  37. [37]
    Waugh, N.R., et al., Mortality in a cohort of diabetic patients. Causes and relative risks. Diabetologia, 1989. 32(2): p. 103–104PubMedCrossRefGoogle Scholar
  38. [38]
    Sturrock, N.D., et al., Non-dipping circadian blood pressure and renal impairment are associated with increased mortality in diabetes mellitus. Diabet Med, 2000. 17(5): p. 360–364PubMedCrossRefGoogle Scholar
  39. [39]
    Epstein, M. and J.R. Sowers, Diabetes mellitus and hypertension. Hypertension, 1992. 19(5): p. 403–418PubMedCrossRefGoogle Scholar
  40. [40]
    Farmer, C.K., et al., Progression of diabetic nephropathy—is diurnal blood pressure rhythm as important as absolute blood pressure level? Nephrol Dial Transplant, 1998. 13(3): p. 635–639PubMedCrossRefGoogle Scholar
  41. [41]
    Verdecchia, P., et al., Blunted nocturnal fall in blood pressure in hypertensive women with future cardiovascular morbid events. Circulation, 1993. 88(3): p. 986–992PubMedCrossRefGoogle Scholar
  42. [42]
    Borch-Johnsen, K., P.K. Andersen, and T. Deckert, The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 1985. 28(8): p. 590–596PubMedCrossRefGoogle Scholar
  43. [43]
    Hansen, H.P., et al., Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy. Kidney Int, 1996. 50(2): p. 579–585PubMedCrossRefGoogle Scholar
  44. [44]
    Lurbe, E., et al., Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med, 2002. 347(11): p. 797–805PubMedCrossRefGoogle Scholar
  45. [45]
    Lurbe, A., et al., Altered blood pressure during sleep in normotensive subjects with type I diabetes. Hypertension, 1993. 21(2): p. 227–235PubMedCrossRefGoogle Scholar
  46. [46]
    Moore, W.V., et al., Ambulatory blood pressure in type I diabetes mellitus. Comparison to presence of incipient nephropathy in adolescents and young adults. Diabetes, 1992. 41(9): p. 1035–1041PubMedCrossRefGoogle Scholar
  47. [47]
    Lafferty, A.R., G.A. Werther, and C.F. Clarke, Ambulatory blood pressure, microalbuminuria, and autonomic neuropathy in adolescents with type 1 diabetes. Diabetes Care, 2000. 23(4): p. 533–538PubMedCrossRefGoogle Scholar
  48. [48]
    Felicio, J.S., et al., Nocturnal blood pressure fall as predictor of diabetic nephropathy in hypertensive patients with type 2 diabetes. Cardiovasc Diabetol, 2010. 9: p. 36PubMedCrossRefGoogle Scholar
  49. [49]
    Magri, C.J., et al., Factors associated with diabetic nephropathy in subjects with proliferative retinopathy. Int Urol Nephrol, 2011Google Scholar
  50. [50]
    Ip, M.S., et al., Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med, 2002. 165(5): p. 670–676PubMedCrossRefGoogle Scholar
  51. [51]
    Ozol, D., et al., Influence of snoring on microalbuminuria in diabetic patients. Sleep Breath, 2010Google Scholar
  52. [52]
    Netzer, N.C., et al., Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med, 1999. 131(7): p. 485–491PubMedCrossRefGoogle Scholar
  53. [53]
    Hovind, P., et al., Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes, 2009. 58(7): p. 1668–1671PubMedCrossRefGoogle Scholar
  54. [54]
    Kosugi, T., et al., Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol, 2009. 297(2): p. F481–488PubMedCrossRefGoogle Scholar
  55. [55]
    Kanakamani, J., et al., Prevalence of microalbuminuria among patients with type 2 diabetes mellitus—a hospital-based study from north India. Diabetes Technol Ther, 2010. 12(2): p. 161–166PubMedCrossRefGoogle Scholar
  56. [56]
    Hoefield, R.A., et al., The use of eGFR and ACR to predict decline in renal function in people with diabetes. Nephrol Dial Transplant, 2010Google Scholar
  57. [57]
    Rossing, P., et al., Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. Diabetes Care, 2006. 29(5): p. 1024–1030PubMedCrossRefGoogle Scholar
  58. [58]
    Phillips, A.O. and R. Steadman, Diabetic nephropathy: the central role of renal proximal tubular cells in tubulointerstitial injury. Histol Histopathol, 2002. 17(1): p. 247–252PubMedGoogle Scholar
  59. [59]
    Kanauchi, M., H. Nishioka, and T. Hashimoto, Oxidative DNA damage and tubulointerstitial injury in diabetic nephropathy. Nephron, 2002. 91(2): p. 327–329PubMedCrossRefGoogle Scholar
  60. [60]
    Nielsen, S.E., et al., Urinary liver-type fatty acidbinding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care, 2010. 33(6): p. 1320–1324PubMedCrossRefGoogle Scholar
  61. [61]
    Kamijo-Ikemori, A., et al., Clinical Significance of Urinary Liver-Type Fatty Acid Binding Protein in Diabetic Nephropathy of Type 2 Diabetic Patients. Diabetes Care, 2011Google Scholar
  62. [62]
    Nielsen, S.E., et al., Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int, 2011. 79(10): p. 1113–1118PubMedCrossRefGoogle Scholar
  63. [63]
    Aaltonen, P., et al., Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy. Lab Invest, 2001. 81(9): p. 1185–1190PubMedCrossRefGoogle Scholar
  64. [64]
    Luimula, P., et al., Nephrin in experimental glomerular disease. Kidney Int, 2000. 58(4): p. 1461–1468PubMedCrossRefGoogle Scholar
  65. [65]
    Qipo, A., H.W. Cohen, and B. Jim, 256 Urinary Nephrin as an Early Biomarker of Diabetic Nephropathy. American journal of kidney diseases: the official journal of the National Kidney Foundation, 2011. 57(4): p. B80CrossRefGoogle Scholar
  66. [66]
    Rutter, M.K., et al., Increased left ventricular mass index and nocturnal systolic blood pressure in patients with Type 2 diabetes mellitus and microalbuminuria. Diabet Med, 2000. 17(4): p. 321–325PubMedCrossRefGoogle Scholar
  67. [67]
    Suzuki, K., et al., Left ventricular mass index increases in proportion to the progression of diabetic nephropathy in Type 2 diabetic patients. Diabetes Res Clin Pract, 2001. 54(3): p. 173–180PubMedCrossRefGoogle Scholar
  68. [68]
    Moon, S.J., et al., The effect of anemia and left ventricular geometric patterns on renal disease progression in type 2 diabetic nephropathy. J Nephrol, 2011. 24(1): p. 50–59PubMedCrossRefGoogle Scholar
  69. [69]
    Rigalleau, V., et al., Large kidneys predict poor renal outcome in subjects with diabetes and chronic kidney disease. BMC Nephrol, 2010. 11: p. 3PubMedCrossRefGoogle Scholar
  70. [70]
    Zerbini, G., et al., Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes. Diabetes, 2006. 55(9): p. 2620–2625PubMedCrossRefGoogle Scholar
  71. [71]
    Ablett, M.J., et al., How reliable are ultrasound measurements of renal length in adults? Br J Radiol, 1995. 68(814): p. 1087–1089PubMedCrossRefGoogle Scholar
  72. [72]
    Elliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis. 2009 Mar;16(2):94–100PubMedCrossRefGoogle Scholar
  73. [73]
    Keithi-Reddy SR, Addabbo F, Patel TV, Mittal BV, Goligorsky MS, Singh AK. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int. 2008Google Scholar
  74. [74]
    Inrig JK, Bryskin SK, Patel UD, Arcasoy M, Szczech LA. Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors. BMC Nephrol. 2011 Dec 12;12:67PubMedCrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of Internal MedicineThomas Jefferson University HospitalPhiladelphiaUSA
  2. 2.Renal DivisionBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA

Personalised recommendations